We are live on
!
Find out more
Bellevue Group Portfolio holdings
AUM
$4.75B
Turnover
23.84%
1-Year Est. Return
68.58%
This Fund
S&P 500
This Quarter
Est. Return
+1.11%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.2B
AUM Growth
-$1.07B
(-20%)
Cap. Flow
-$834M
Cap. Flow
% of AUM
-19.85%
Top 10 Holdings %
Top 10 Hldgs %
41.95%
Holding
195
New
19
Increased
34
Reduced
87
Closed
40
Avg Time Held
3.8
years
Top 10 Avg Time Held
2.6
years
Top 20 Avg Time Held
2.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$203M |
| 2 |
Gilead Sciences
GILD
|
+$156M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
+$146M |
| 4 |
Amgen
AMGN
|
+$98.7M |
| 5 |
Viridian Therapeutics
VRDN
|
+$70.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$350M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$235M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$225M |
| 4 |
RNAM
Avidity Biosciences
RNAM
|
+$190M |
| 5 |
Amicus Therapeutics
FOLD
|
+$153M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.74% |
| 2 | Energy | 0.07% |
| 3 | Technology | 0.06% |
| 4 | Miscellaneous | 0.05% |
| 5 | Financials | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Illumina
ILMN
$40.5B
| $2.49M | 0.06% |
20,223
-2,717
| -12% | -$357K |
2016 Q1
40 quarters
|
|
77
Kestra Medical Technologies
KMTS
$1.71B
| $2.3M | 0.05% |
115,590
-165
| -0.1% | -$3.89K |
2025 Q1
4 quarters
|
|
78
Omada Health Inc
OMDA
$1.14B
| $1.99M | 0.05% |
157,938
-19,959
| -11% | -$276K |
2025 Q2
3 quarters
|
|
79
BridgeBio Pharma
BBIO
$13.1B
| $1.88M | 0.04% |
25,377
+1,266
| +5% | +$91.8K |
2023 Q1
12 quarters
|
|
80
BioNTech
BNTX
$22.7B
| $1.85M | 0.04% |
20,851
-22,904
| -52% | -$2.35M |
2024 Q3
6 quarters
|
|
81
Royalty Pharma
RPRX
$26.5B
| $1.84M | 0.04% |
38,296
+25,095
| +190% | +$1.1M |
2025 Q3
2 quarters
|
|
82
State Street SPDR S&P 500 ETF Trust
SPY
$815B
| $1.76M | 0.04% |
2,700
-400
| -13% | -$272K |
2024 Q4
5 quarters
|
|
83
Insmed
INSM
$21.7B
| $1.64M | 0.04% |
10,034
-3,881
| -28% | -$597K |
2018 Q1
32 quarters
|
|
84
Madrigal Pharmaceuticals
MDGL
$10.6B
| $1.59M | 0.04% |
3,040
+156
| +5% | +$74.5K |
2024 Q1
8 quarters
|
|
85
DELISTED
Masimo
MASI
| $1.56M | 0.04% |
8,753
-88,532
| -91% | -$13.9M |
2024 Q4
5 quarters
|
|
86
Protagonist Therapeutics
PTGX
$8.84B
| $1.52M | 0.04% |
14,447
-2,096
| -13% | -$186K |
2023 Q3
10 quarters
|
|
87
United Therapeutics
UTHR
$23.2B
| $1.23M | 0.03% |
2,077
-1,818
| -47% | -$905K |
2025 Q3
2 quarters
|
|
88
BeOne Medicines Ltd
ONC
$42.3B
| $1.13M | 0.03% |
3,812
+1,922
| +102% | +$622K |
2022 Q3
14 quarters
|
|
89
Phreesia
PHR
$685M
| $1.1M | 0.03% |
130,992
-52,221
| -29% | -$691K |
2019 Q3
26 quarters
|
|
90
Adaptive Biotechnologies
ADPT
$4.08B
| $1.06M | 0.03% |
76,181
-221,909
| -74% | -$3.54M |
2025 Q3
2 quarters
|
|
91
Bristol-Myers Squibb
BMY
$124B
| $1.03M | 0.02% |
17,038
-50,044
| -75% | -$2.92M |
2024 Q3
6 quarters
|
|
92
Encompass Health
EHC
$12.6B
| $951K | 0.02% |
9,829
-9,260
| -49% | -$950K |
2023 Q4
9 quarters
|
|
93
NewAmsterdam Pharma
NAMS
$2.46B
| $885K | 0.02% |
27,661
-8,675
| -24% | -$283K |
2024 Q3
6 quarters
|
|
94
Apple
AAPL
$4.99T
| $843K | 0.02% |
3,320
| – | – |
2025 Q3
2 quarters
|
|
95
BillionToOne Inc
BLLN
$4.85B
| $833K | 0.02% |
10,554
-35
| -0.3% | -$2.87K |
2025 Q4
1 quarter
|
|
96
Mineralys Therapeutics
MLYS
$1.91B
| $796K | 0.02% |
29,374
+9,548
| +48% | +$280K |
2024 Q1
8 quarters
|
|
97
Equinor
EQNR
$106B
| $742K | 0.02% |
+17,573
| New | +$530K |
2026 Q1
0 quarters
|
|
98
ExxonMobil
XOM
$718B
| $741K | 0.02% |
+4,370
| New | +$638K |
2026 Q1
0 quarters
|
|
99
BP
BP
$125B
| $735K | 0.02% |
+15,644
| New | +$613K |
2026 Q1
0 quarters
|
|
100
Shell
SHEL
$295B
| $729K | 0.02% |
+7,844
| New | +$634K |
2026 Q1
0 quarters
|
|
Similar funds
PTC
Bellevue Group's Q1 2026 Portfolio in Review
As of Q1 2026, Bellevue Group held 195 positions worth $4.2B, down 20% from $5.28B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Bellevue Group withdrew a net $834M in Q1 2026, closing 40 positions and reducing 87 holdings. Its most notable exit was Avidity Biosciences, an estimated $190M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Energy and Technology.
Against the trend, Bellevue Group opened a new position in Vaxcyte worth $69.2M.
- Bellevue Group's largest Q1 2026 buy was Vaxcyte: 1,190,697 shares worth $69.2M.
- Bellevue Group added most to Regeneron Pharmaceuticals in Q1 2026, an estimated $203M increase.
- Bellevue Group's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $350M.
- Bellevue Group fully exited Avidity Biosciences in Q1 2026, selling an estimated $190M.
- Bellevue Group's ten largest holdings make up 42% of its $4.2B portfolio in Q1 2026.
- Bellevue Group opened 19 new positions and closed 40 in Q1 2026.
- Bellevue Group's portfolio value fell 20% quarter-over-quarter to $4.2B.
Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.